Insulet Corp. reported changes to the responsibilities of key members of its Board of Directors and Management team: Patrick Sullivan, President and Chief Executive Officer since September 2014, has been elected Chairman of the Board. He will continue to serve as Chief Executive Officer. Dr. Jessica Hopfield, Director since July 2015, has been appointed Lead Independent Director of the Board. Dr. Hopfield succeeds Dr. John Fallon, who will continue to serve on the Board as an independent director. Dr. Hopfield also serves as Chairperson of the Board of Trustees of the Joslin Diabetes Center and is a strategic advisor and investor in start-up healthcare firms. She previously was a partner of McKinsey & Company in their Global Pharmaceuticals and Medical Devices Practice. Shacey Petrovic, President, Diabetes Products since February 2016, after joining the Company as Chief Commercial Officer in February 2015, has been promoted to President and Chief Operating Officer. In this position, she will work closely with Sullivan to further improve Insulet's operational capabilities and capitalize on new growth opportunities, and will be responsible for overseeing the Company's Drug Delivery product line. Daniel Levangie, President, Drug Delivery, has informed the company he will retire at the end of 2016. Petrovic will assume Levangie's responsibilities and Levangie will continue with the company through the end of the year to assist with an effective transition. He will then remain available to the company in a consulting role.